On April 15, 2026 Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule protein sequencing, reported that there will be two customer posters presented at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) annual meeting on April 17-22, 2026 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster 2421; April 20, 2026
Primary Author: Nigel O’Neil, PhD
Poster Title: Combining deep mutational scanning and next-generation protein sequencing to harness dominant protein variants to develop DNA repair inhibitors
In the first poster, the researchers describe a complementary genetic (high throughput screens) and proteomic (benchtop protein sequencing) approach to find and model the behavior of therapeutics targeting DNA repair enzymes.
Poster 7650; April 22, 2026
Primary Author: Gloria Sheynkman, PhD
Poster Title: High-resolution detection of post-translational modifications using single-molecule protein sequencing
In the second poster, the researchers demonstrated the ability to resolve and quantify multiple PTMs using Quantum-Si’s single-molecule protein sequencing technology. The authors suggested that the technology could be used to add proteoform characterization to biomarker studies, providing additional resolution not readily available in broad biomarker screening panels. The authors further concluded that they expect this technology could democratize advanced protein characterization, making the high-resolution detection of PTMs available to a broader scientific community.
"We are excited to see new customer data being presented at key industry conferences like AACR (Free AACR Whitepaper), that continue to demonstrate the power of our proprietary single-molecule protein sequencing technology," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "We invested significant effort during 2025 to build a pipeline of studies that would demonstrate the power of our technology, and we are very pleased to have a steady flow of customer pre-prints, publications and posters being released this year as we work to expand awareness and build momentum towards the launch of Proteus."
(Press release, Quantum SI, APR 15, 2026, View Source [SID1234664420])